Amphastar Pharmaceuticals has received FDA approval for succinylcholine chloride injection USP, 200 mg/10mL multiple-dose vials as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

The new product is therapeutically equivalent to Pfizer’s Quelicin. According to Amphastar, IQVIA data showed that succinylocholine chloride injection USP, 200 mg/10 mL made approximately $75 million in United States market annual sales for the 12 months prior to March 31, 2020.


Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial [news release]. Amphastar Pharmaceuticals; June 9, 2020. Accessed June 9, 2020.